[-] Show simple item record

dc.contributor.authorWinklerPrins, Vincent J.eng
dc.contributor.authorWeismantel, Arlene McFarlineng
dc.date.issued2004eng
dc.description.abstractColchicine (strength of recommendation [SOR]: B, based on 1 double-blind crossover study), allopurinol (SOR: B, based on 2 cohort studies), and weight loss (SOR: B, based on 1 small cohort study) have been shown to reduce symptomatic recurrences of gout, although the data to support their use is limited. Some evidence suggests that despite their serum uric acid-lowering effects, uricosurics (such as probenecid) fail to reduce gout attacks (SOR: B, based on 2 cohort studies). We were unable to find any double-blind, placebo-controlled long-term outcome studies addressing this problem.eng
dc.identifier.urihttp://hdl.handle.net/10355/3075eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2004 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 53, no. 10 (October 2004): 837-838.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjecturicosuricseng
dc.subjectinflammatory responseeng
dc.subject.lcshWeight losseng
dc.subject.lcshGouteng
dc.subject.lcshColchicineeng
dc.titleHow effective is prophylactic therapy for gout in people with prior attacks?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record